PASGAfter a double bottom a small triangle has formed, the brekkout of this triangle could project towards 2.80, otherwise a return to the lows
Biotech
BCDA Short AnalysisBCDA has an upcoming CardiAMP Heart Failure DSMB review on the 30th of this month (August). Although the treatment indicated no significant safety concerns, I have reasonable doubt that this won't go through to be accepted by the FDA; the Phase III to NDA/BLA is about a 58.1% chance, the NDA/BLA to Approval is a 85.3% chance, and then the Phase I to Approval is a 9.6% chance. BioCardia has 6 treatments that are under trials and the CardiAMP Ischemic Heart Failure treatment is the closest to approval. If this treatment doesn't get approved, everything will rip apart and the market for this will plunge. Chart-wise, there is a consistent downtrend on the 1-Day mark. If you are putting a short position on this, I highly recommend you to have buy-stop orders.
MNMD Biotech Penny Stock SHORT SETUPNASDAQ:MNMD
Yj
This stock had a quick response to good earnings and
it is now at resistance with the RSI swing indicator
printing a Sell Signal.
The MACD, a lagging indicator, shows the signal
above the histogram without a K / D cross
not yet started.
I would like to take a short trade setting a stop loss
above the resistance zone and targeting 10%
to the POC line of the volume profile sitting above
the support zone.
Please comment and offer your opinion.
3
bearish butterfly pattern 30min time frame on $labdmonitoring the bearish butterfly pattern set up on $labd.. I'm looking for the previous resistances to act as support. If both levels fail, then the bearish butterfly pattern looks to be confirm, and I will short to C leg.
LABU 3X Leverage BIOTECHNOLOGY a potential Recession playLABU a 3x leveraged EFT in the biotechnology sector has diverse holdings.
My thesis is that biotechnology and healthcare are relatively unhinged from the broader general market.
Here I chart LABU / QQQ ratio to determine relative strength.
On this weekly chart, the ratio and so relative strength are at more than a 52 week low.
The MACD indicator shows the MACD and signal line ascending and below the histogram.;
moreover the MACD in green is running above the signal line. This favors a trend reversal.
All in all, this seems to be a setup for a long swing trade or investment.
I will take a trade in a call option with a strike 50% higher than current price
as I see a potential for a large percentage gain for LABU. The diversity of the ETF
will serve to mitigate some of the risk. A stop loss will be 1% below current price
with an expectation of more than a 50 % return in the remainder of the calendar
year but far more in the case of the call option scenario
money flowing into biotech sectorxbi is displaying strength on the daily as far as qqe and sss strategies are concerned. if we stay above pivot im targeting upper horizontals as rising 4hr triangle could bull pennant, and if we fall beneath that pivot resisting from rising 4hr triangle i would target lower horizontals.
IMGN - ImmunoGen, Inc.Setup - simple base breakout after a solid 70% move off the lows followed by 5 weeks of consolidation. Earnings during consolidation were below expectation. However, after a slight selloff, shares were gobbled back up and volatility was squeezed out right below the breakout level. Half size because the broad market is running a bit hot and could be due for a pullback relatively soon.
PFE trianglePFE reached the bottom of the triangle AGAIN. I added of lows today to my current position. Still holding this dividend cash cow. It looks like something that's going to eat you! But the trend line works magic. Nice longer swing or LT hold for me. Not day trading this one, moving too slow.
NVTA Breakout after EarningsNYSE:NVTA
a NASDAQ Penny Stock moving 10% today
after an earnings loss with a pullback and rebound.
Speculative but possibly with a good risk to reward
since it has already pulled back. Stochastic RSI
is low and all of this follows a long period
of consolidation. RElative up volume today
is 10-15X baseline showing good
accumulation.
Options for January 23 show reasonable volume
Put/Call ratio of 0.45 and volatility about 100%
NVTA Parabolic from long consolidation then a pullback
now setup for entry
HOURLY CHART shows consolidation and
parabolic breakout with a pullback to
entry point
Awesome Indicator is supportive.
The catalyst was a good bear on earnings.
UBX ( NASDAQ BIOTECH PENNY) crushes earnings and news catalystNASDAQ:UBX
and rises over 100 % in premarket, Has a new product
for macular degeneration, a widespread medical problem
affecting vision in the elderly which is increasing
in incidence. The earning beat was significant.
Chart demonstrates the uptrend and midrange
RSI but does not show today's premarket.
40 % rise in the week leading up to earnings and now parabolic.
doubling overnight.
* Get in the party now, don't be late. If you are
late stay home"
( not a recommendation to buy only education)
ASND ( NASDAQ BIOTECH) rises on earnings and FDA submissionNASDAQ:ASND
as can be seen on the hourly chart ASND is in an uptrend
recent earnings were a good beat,
RSI is quite high and it is at one than one STD above
the multi-session VWAP.
ASND is on watch for a pullback to find an entry
as it has high upside.
NVTA Invitae Corporation Options Ahead Of EarningsLooking at the NVTA Invitae Corporation options chain, i would buy the $2.5 strike price calls with
2023-1-20 expiration date for about
$0.60 premium.
Looking forward to read your opinion about it.
$NTRA Natera Channel BreakNatera breaking out of a defined channel. Possible target would be gap close around $52,52
$XBI Biotech ETF. Looking bullishBiotech has been hammered since Feb 2021. This ETF is still down 50% + from it's all time high.
It formed a double bottom and now a small bullish flag.
Target is 97. Longer term 122,134
NVAX… once a loser always a loserthe inability of NVAX to properly capitalize on the covid vaccine is a sign of a poorly managed company. was the rise from near penny status exceptional? of course. was the following wealth destruction of epic proportions? sure was.
endless upset longs continue to exit as all good news acts as a selling event. this will be a ride back to single digits for a company who, pre-covid, could not get a single ball across the goal line.
Biotech: textbook bullish continuation pattern breakoutBiotech was one of the first sectors in the market to show relative strength and catch some bids throughout the June bottoming process.
IBB rallied 20% off the lows and then proceeded to consolidate sideways for 3 weeks. This Wednesday, IBB broke out of that consolidation with a gap up on heavy volume and is now finding more follow-through.
Keep an eye on the old Feb/Apr highs around 135 which seems like the next target in this uptrend.
BNTX will pop-up on next earnings dayBNTX will pop-up on next earnings day.
Technicals suggest the stock has been building a bottom the last couple of months. Now is well above the 50 day EMA and it is begining to challenge the 200 day EMA.
The P/E ratio and Forward P/E ratio are in the low single digits.
I expanded my position when BNTX crossed above the 50 day EMA.
8/3/22 MRNAModerna, Inc. ( NASDAQ:MRNA )
Sector: Health Technology (Biotechnology)
Market Capitalization: $74.178B
Current Price: $186.49
Breakout Price: $189.50
Buy Zone (Top/Bottom Range): $180.95-$147.05
Price Target: $204.50-$208.80 (1st), $258.80-$263.70 (2nd)
Estimated Duration to Target: 34-37d, 91-96d
Contract of Interest: $MRNA 9/16/22 190c, $MRNA 10/21/22 200c
Trade price as of publish date: $13.96/contract, $15.55/contract
Looking at a short on NVTA- Here's whyHello TradingView!
I'm Fomo Sapien, a 13 year old trader focusing on stock swing trades.
Today, I'd like to share a stock I've been keeping an eye on for a bit- NVTA (Invitae Corp).
I found this stock using the Finviz stock screener.
I'm looking to short NVTA because of the technical chart- I want to make it clear that I do not and have not done fundamental analysis on this stock beside a bare minimum google search.
Anyway, let's talk about the chart.
As you can see from the visual, I'm looking to short right around this level (2.08), and I want to short due to the recent consolidation into s/r and ema resistance. If I enter the trade, I will be updating this post with my target(s) and stop loss.
Earning are expected on August 9th, with an analyst estimate of a 76 cent loss per share. While this further confirms my short idea, I would plan to exit the trade before earnings regardless- although I am open to a re-entry if the setup doesn't change afterwards.
The current price is $2.07 so, following this idea, you could short at the open. Remember I have not entered the trade and this post is more of a heads up- as previously mentioned I'll post an update below if/when I enter the trade.
Happy Trading!
Fomo
Breakthrough Discovery: AccuTOX Effectively Kills Cancer Cells by @newsfile on 2 Aug 2022, 03:15
Breakthrough Discovery: AccuTOX(TM) Effectively Kills Cancer Cells by Directly Eliciting DNA Damage
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the discovery of a novel DNA damaging function triggered by one of its lead compounds AccuTOXTM, which effectively elicits cell death in cancer cells.
Cancer can be generally described as a state of uncontrolled cell proliferation. This is mainly due to losses in the ability of a given cell to activate its own cell death via a specific set of proteins known to sense unusual activities. Although it is difficult to reactivate these specific pathways to elicit cancer cell death, AccuTOXTM can address this.
Defence previously reported (see press release of June 22, 2021) the discovery of an AccumTM variant, AccuTOXTM, capable of controlling cancer growth when injected directly in tumors. The use of AccuTOXTM in combination with multiple immune-checkpoints results in a survival rate between 60% and 100%, based on the pre-clinical tumor models studies in mice. The mode of action of AccuTOXTM approached is a non-biased transcriptomic application and revealed that the compound impairs several crucial pathways including DNA replication, cell division, nuclear integrity, and multiple modifications affecting DNA activity. The accumulation of exhaustive cell repair mechanisms triggered by AccuTOXTM combined to the build-up of misfolded proteins and generation of free radicals induce irreversible DNA damages leading to a general collapse in several cellular pathways resulting in effective cancer cell death.
"Defence's breakthrough discovery with its AccuTOXTM formulation as a novel potent small molecule capable of killing cancer cells is a significant advancement and development for oncology cancer treatment applications with AccumTM. Discovering that AccuTOXTM can behave as a chemotherapeutic agent targeting the DNA of cancer cells and an immune-checkpoint inhibitor booster is a new discovery that is highly valuable to Defence's pipeline and future potential developments. The AccuTOXTM presents a novel discovery as a platform for targeting multiple cancers. This novel discovery creates significant values and applications to our Antibody Drug Conjugate ("ADC") pipeline. Results are convincing that AccuTOXTM is the perfect potent small molecule to use in the development of our own ADC," says Mr. Plouffe, the CEO of Defence Therapeutics.
Defence is currently conducting GLP studies on AccuTOXTM prior to initiate a Phase I trial in North America.
MRNA - SHORT THESISBearish on MRNA, though earnings are always a toss up. If we see a breakout to upside, I believe it's a good short opportunity. Earnings may just flop, and it finds itself testing neckline of weekly H&S, sloppy looking one at that.
Notable areas that could see short term reversals and/or support...
$102, 95, 88, 75
PFE not making it through the trendline againPFE is touching the diagonal trendline to the upside again. Can't wait for the breakout. LT holding with nice dividend.
